Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | FDPS | P14324 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | ARG1 | P05089 | 1/20 | 0.42 |
| ▸ | ARG2 | P78540 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15189769 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2HIF1ACYP2C9CYP2C19CYP1A2 | |
| SCHEMBL4975583 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2HIF1ACYP2C9CYP2C19CYP1A2 | |
| SCHEMBL2036359 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2HIF1ACYP2C9CYP2C19CYP1A2 | |
| SCHEMBL2032810 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2HIF1ACYP2C9CYP2C19CYP1A2 | |
| SCHEMBL9817479 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2HIF1ACYP2C9CYP2C19CYP1A2 | |
| SCHEMBL28125890 | 0.82 | HIF1A (0.55) | SMN1; SMN2HIF1ACYP2C9CYP2C19CYP1A2 | |
| SCHEMBL419615 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2HIF1ACYP2C9CYP2C19CYP1A2 | |
| SCHEMBL244942 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2HIF1ACYP2C9CYP2C19CYP1A2 | |
| SCHEMBL3805248 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2HIF1ACYP2C9CYP2C19CYP1A2 | |
| SCHEMBL13519211 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2HIF1AALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116271245-A | Bionic tendon sheath membrane with medicine slow-release function and preparation method thereof | 河北医科大学第三医院 | 2023-06-23 | — | — | CN | claimed |
| US-8778069-B2 | Phase change inks containing oligomeric rosin esters | XEROX CORPORATION (US) | 2014-07-15 | — | — | US | claimed |
| US-20140137767-A1 | Phase Change Inks Containing Oligomeric Rosin Esters | XEROX CORPORATION (US) | 2014-05-22 | — | — | US | claimed |
| EP-1919909-B1 | SYNTHETIC METHODS AND INTERMEDIATES FOR STEREOISOMERIC COMPOUNDS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARMETHEON INC (US) | 2013-08-21 | — | — | EP | claimed |
| WO-2009084024-A2 | A PROCESS FOR THE PREPARATION OF R-SIT AGLIPTIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | GLENMARK GENERICS LIMITED (IN) | 2009-07-09 | — | — | WO | claimed |
| JP-9012515-A | — | — | None | — | — | JP | disclosed |
| CN-112839715-B | Process for producing compound for inhibiting SHP2 activity | 诺华股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-12138262-B2 | Process of manufacture of a compound for inhibiting the activity of SHP2, as well as products resulting from acid addition | NOVARTIS AG (CH) | 2024-11-12 | — | — | US | disclosed |
| EP-3807243-B1 | A NOVEL PROCESS FOR THE PREPARATION OF TAPENTADOL | PHARMATHEN SA (GR) | 2024-05-22 | — | — | EP | disclosed |
| CN-112424177-B | One-pot organic pseudo-catalytic C-H activation method for preparing vortioxetine and vortioxetine intermediate | VIO制药公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20240024312-A1 | PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-01-25 | — | — | US | disclosed |
| US-11851503-B2 | Antiplasmodial compounds | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| EP-1019434-A2 | INHIBITORS OF METALLOPROTEINASES, THEIR THERAPEUTIC USE, AND PROCESS FOR THE PRODUCTION OF THE STARTING COMPOUND IN THEIR SYNTHESIS | POLIFARMA S.p.A. (IT) | 2000-07-19 | — | — | EP | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-2000010551-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2000-03-02 | — | — | WO | disclosed |
| CN-1225631-A | Bioconjugates of manganese or iron complexes of nitrogen-contg. macrocyclic ligands effective as catalysis for dismutating superoxide | MONSANTO CO (US) | 1999-08-11 | — | — | CN | disclosed |
| WO-1999003878-A2 | INHIBITORS OF METALLOPROTEINASES, THEIR THERAPEUTIC USE, AND PROCESS FOR THE PRODUCTION OF THE STARTING COMPOUND IN THEIR SYNTHESIS | POLIFARMA S.P.A. (IT) | 1999-01-28 | — | — | WO | disclosed |
| JP-H0912515-A | PRODUCTION OF OPTICALLY ACTIVE 1-(2,4-DICHLOROPHENYL) ETHYLAMINE | SUMITOMO CHEM CO LTD | 1997-01-14 | — | — | JP | disclosed |
| US-4571424-A | SALT FORMATION WITH MANDELIC ACID, PRECIPITATION AND EXTRACTION | A/S FERROSAN (DK) | 1986-02-18 | — | — | US | disclosed |
| JP-H00912515-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024312-A1 | PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN | DPP4, NT5C, DPP7 | SMN1; SMN2 596/4885HIF1A 4204/4885CYP2C9 274/4885 |
| US-12138262-B2 | Process of manufacture of a compound for inhibiting the activity of SHP2, as well as products resulting from acid addition | PTPN5, PTPN7, PTPN1 | SMN1; SMN2 3575/4885HIF1A 3982/4885CYP2C9 2018/4885 |
| US-11851503-B2 | Antiplasmodial compounds | MGST3, G6PD, GPX4 | SMN1; SMN2 2960/4885HIF1A 4082/4885CYP2C9 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.